DGAP-News: MOLOGEN AG: Approval-relevant clinical trial with colorectal cancer medicine MGN1703 also started in Russia
(firmenpresse) - DGAP-News: MOLOGEN AG / Key word(s): Miscellaneous
MOLOGEN AG: Approval-relevant clinical trial with colorectal cancer
medicine MGN1703 also started in Russia
28.04.2011 / 09:00
---------------------------------------------------------------------
- Approval granted for clinical trial II/III in Russia
- Amendment of the Russian drug law led to delay
- Commencement of the intermediate evaluation expected in the 2nd half of
2011
Berlin, 28. April 2011 - MOLOGEN AG is now starting the implementation of a
clinical trial II/III with the colorectal cancer medicine MGN1703 in
Russia. This means that alongside Germany, France and Austria, MOLOGEN is
present in a further important and large market. The clinical trial is to
be carried out in study centers in the Greater Moscow area and other
Russian cities.
MOLOGEN AG had been waiting with some tension for commencement of the trial
in Russia, since the approval process took place at the same time as the
extensive amendment to the Russian drug law and changes in official
responsibilities. This led to a delay in the start of the study there.
Commencement of the intermediate evaluation expected in the 2nd half of
2011 MOLOGEN AG currently expects to be able to commence the intermediate
evaluation of the international clinical trial II/III with MGN1703 in the
2nd half of this year. Dr. Matthias Schroff, CEO of MOLOGEN AG, stated: 'We
are pleased that we can now finally commence the trial with MGN1703 in
Russia. Even today, the compound is already proving its excellent
compatibility in all study centers. As shown by the previous progress of
the trial, the design of the clinical trial II/III for the colorectal
cancer medicine MGN1703 has been very well accepted by the trial doctors
and the patients.' Similar progress is expected in Russia.
Patient information
www.mologen.com/data/English/03_08_Patientinfo.shtml
Study portal
The study is recorded on all relevant Internet portals. To overview see
website:
www.mologen.unternehmenskommunikation.com/D/studienportale
Hotline
A study hotline at MOLOGEN AG for MGN1703 provides information individually
and in strict confidence in accordance with medical discretion to
interested doctors and patients on:
+49 (0)800 646 1703
www.mologen.com
About MOLOGEN AG
Die MOLOGEN AG, a German biopharmaceutical company with headquarters in
Berlin specializes in the research and development of innovative
medications on the basis of DNA structures. The activities focus on
numerous product developments which are relevant to the immune system; on
the one hand vaccines against infectious diseases and on the other hand
cancer medications. MOLOGEN AG is globally one of the few biotechnology
companies with well tolerated DNA-based cancer treatment in the clinical
development phase.
The stocks of MOLOGEN AG are listed in the Prime Standard of the German
stock exchange
(ISIN DE0006637200).
Memberships in associations:
BIO Deutschland e.V. | DECHEMA - Society for chemical technology and
biotechnology e.V. | German industrial association of biotechnology (DIB)
| Association for the Promotion of Science and Humanities in Germany |
Association of German biotechnology companies (VBU) | Association of
researching manufacturers of pharmaceuticals e.V. (VFA) | Association of
the chemical industry e.V. (VCI)
MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
MOLOGEN AG
PRESS SERVICE
Prof. Peter W. Huebner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Tel: +49 - 30 - 84 17 88 - 50
huebner(at)mologen.com
INVESTOR RELATIONS:
MOLOGEN AG:
Joerg PetraßTel: +49 - 30 - 84 17 88 - 13
Tel: +49 - 30 - 84 17 88 - 50
investor(at)mologen.com
External Investor Relations
Kirchhoff Consult AG
Janina Wismar
T: +49 - 40 - 60 91 86 - 50
F: +49 - 40 - 60 91 86 -16
janina.wismar(at)kirchhoff.de
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.
End of Corporate News
---------------------------------------------------------------------
28.04.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Deutschland
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info(at)mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
121663 28.04.2011
Datum: 28.04.2011 - 09:00 Uhr
Sprache: Deutsch
News-ID 33888
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: MOLOGEN AG: Approval-relevant clinical trial with colorectal cancer medicine MGN1703 also started in Russia"
steht unter der journalistisch-redaktionellen Verantwortung von
MOLOGEN AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
